ChargePoint Holdings Inc (NYSE: CHPT) benefits from a “capital-light” growth model, enjoys a first-mover advantage with integrated solutions and the current valuation of its stock is attractive, according to Credit Suisse.
Capital One analyst Naureen Quibria initiates coverage on Fennec Pharmaceuticals (NASDAQ:FENC) with a Overweight rating and announces Price Target of $11.